Victoria Johnson

Combining golimumab with methotrexate reduced corticosteroid reliance and maintained efficacy in psoriatic arthritis.

The rheumatology month in review emphasizes new approvals and best-in-class efficacy data.

The FDA has approved the therapy, marketed as Wayrilz, a new treatment for chronic immune thrombocytopenia.

Regeneron is planning a BLA submission for the first quarter of 2026.

This FDA News Month in Review provides a round-up of regulatory decisions from August 2025.

Santerus AG is preparing to initiate clinical trials of its blood purification technology in a variety of indications.

Despite high cardiovascular risk with the 2 comorbidities, no beneficial effect was seen with colchicine.

In this feature, 3 experts discuss the management of 2 overlapping conditions: psoriasis and psoriatic arthritis.

A recent study reveals gout patients face higher chronic opioid prescription rates.

Rosnilimab shows promising long-term efficacy in treating moderate-to-severe rheumatoid arthritis.

The therapy, marketed as Tonmya, is a sublingual formulation of cyclobenzaprine HCl.

SetPoint Medical's FDA-approved device offers a new neuroimmune therapy for rheumatoid arthritis, enhancing treatment options without immune risks.

Novartis is planning regulatory submissions for the therapy, which could become the first to meaningfully modify disease activity.

New research reveals challenges in maintaining urate-lowering therapy for gout, highlighting disparities in adherence among diverse patient populations.

New findings reveal CFT outperformed usual care to significantly reduce chronic low back pain and activity limitations.

The rheumatology month in review emphasizes new research in psoriatic arthritis treatments and data from EULAR 2025.

Guselkumab shows promise as the first IL-23 inhibitor to significantly reduce joint damage in active psoriatic arthritis.

Reformer Pilates significantly reduces pain and enhances mental and physical health in women with chronic musculoskeletal pain, promoting active living and coping strategies.

New phase 3 trials reveal tildrakizumab 100mg significantly improves symptoms in active psoriatic arthritis, offering hope for effective treatment options.

Machine learning uncovers gut microbiome biomarkers linked to purine metabolism, enhancing diagnostic strategies for gout and hyperuricemia.

Conversely, influenza vaccine was associated with increased COVID-19 severity and hospitalizations in patients with inflammatory rheumatic diseases.

Bristol Myers Squibb's deucravacitinib shows promise as a safe, effective treatment for active psoriatic arthritis, pending FDA approval by March 2026.

GLP-1 receptor agonists show promise in reducing pain, fatigue, and opioid use in fibromyalgia patients, suggesting a new therapeutic avenue.

TYK2 inhibition may offer a potentially better tolerated treatment option than JAK inhibitors for people with PsA.

A study reveals a significant link between poor oral health and increased migraines and body pain in women, highlighting implications for fibromyalgia management.

Explore groundbreaking FDA approvals and clinical trial advancements in rheumatology, offering new hope for patients with rare autoimmune diseases and chronic conditions.

This FDA News Month in Review provides a round-up of regulatory decisions from June 2025.

The rheumatology month in review emphasizes new research in RA burden, fibromyalgia treatment, and insights from the EULAR 2025 meeting.